Cargando…
The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Currently, chemotherapy is one of the mainstays of oncologic therapies. But the efficacy of chemotherapy is often limited by drug resistance and severe side effects. Consequently, it is becoming increasingly important to investigate the underlying mechanism and overcome the problem of anticancer che...
Autores principales: | Sun, Ruipu, Ying, Ying, Tang, Zhimin, Liu, Ting, Shi, Fuli, Li, Huixia, Guo, Taichen, Huang, Shibo, Lai, Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978646/ https://www.ncbi.nlm.nih.gov/pubmed/31556849 http://dx.doi.org/10.2174/0929866526666190926154248 |
Ejemplares similares
-
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017) -
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022) -
Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021) -
Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016) -
Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy
por: Xiao, Yu‐Feng, et al.
Publicado: (2022)